X
<

How Celgene Is Positioned after 2Q17

PART:
1 2 3 4 5 6 7 8
Part 8
How Celgene Is Positioned after 2Q17 PART 8 OF 8

Luspatercept: Opportunity for Celgene’s Long-Term Growth?

Luspatercept for Myelodysplastic Syndromes

In May 2017, Celgene (CELG) and Acceleron Pharma (XLRN) announced the preliminary results from the ongoing Phase 2 trial with Luspatercept for the treatment of Myelodysplastic Syndromes (or MDS).

In the Phase 2 study, among lower-risk MDS patients, 48% of the erythropoiesis-stimulating agent-naïve1 MDS patients treated with luspatercept achieved red blood cell transfusion independence (or RBC-TI) and 51% of ESA-naïve patients treated with luspatercept achieved a clinically meaningful erythroid hematological improvement (or HI-E). Among patients with prior ESA treatment, 51% of the patients achieved HI-E, and 33% of the patients achieved RBC-TI.

Luspatercept: Opportunity for Celgene’s Long-Term Growth?

Interested in BMY? Don't miss the next report.

Receive e-mail alerts for new research on BMY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In June 2017, Celgene and Acceleron announced the completion of the enrollment of Phase 3 MEDALIST and BELIEVE trials with lupatercept in individuals with MDS and beta-thalassemia.

Initiation of MEDALIST trial

Celgene and Acceleron are conducting the Phase 3 MEDALIST trial to evaluate the safety and efficacy of luspatercept in individuals with ring sideroblasts (or RS+). These individuals are at lower-risk MDS with a baseline RBC transfusion burden of no less than two units per eight weeks over the 16-week period before the treatment.

The primary endpoint of Phase 3 MEDALIST trial is to determine the proportion of patients who are independent to red blood cell (or RBC) transfusion during any successive eight-week period through week 24.

Initiation of BELIEVE trial

Celgene and Acceleron are conducting the Phase 3 BELIEVE trial to evaluate the safety and efficacy of luspatercept in individuals with transfusion-dependent beta-thalassemia. The primary endpoint of the BELIEVE trial would be to determine the proportion of patients achieving a reduction in RBC transfusion burden ≥33% from week 13 to week 24 compared to the baseline 12-week period before therapy.

The Vanguard S&P 500 ETF (VOO) has ~0.50% of its total portfolio holdings in Celgene.

  1. ESA
X

Please select a profession that best describes you: